US Pharma MarketingTeva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.
Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute
Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.
Source: BioPharma Dive